| 摘要 |
A HUMAN ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF AN ANTIBODY THAT SPECIFICALLY BINDS HUMAN CD20 AND IS CAPABLE OF INDUCING COMPLEMENT DEPENDENT CYTOTOXICITY (CDC), AND IS CAPABLE OF INCREASING SYMPTOM FREE SURVIVAL TIME BETWEEN ABOUT 2-FOLD TO ABOUT 9-FOLD OR MORE, RELATIVE TO CONTROL-TREATED ANIMALS IN A MOUSE MODEL OF HUMAN LYMPHOMA. THE ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF IS USEFUL IN A THERAPEUTIC METHOD FOR TREATING A CD20-MEDIATED DISEASE OR CONDITION, SUCH AS FOR EXAMPLE, NON-HODGKIN?S LYMPHOMA, RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, CROHN?S DISEASE, CHRONIC LYMPHOCYTIC LEUKEMIA, AND INFLAMMATORY DISEASES.
|
